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ABSTRACT
Treatment with aromatase inhibitors for postmeno-
pausal women with breast cancer has been shown to
reduce or obviate invasive procedures such as hys-
teroscopy or curettage associated with tamoxifen-
induced endometrial abnormalities. The side effect
of upfront aromatase inhibitors, diminished estrogen
synthesis, is similar to that seen with the natural events
of aging. The consequences often include vasomotor
symptoms (hot flushes) and vaginal dryness and at-
rophy, which in turn may result in cystitis and vagini-
tis. Not surprisingly, painful intercourse (dyspareunia)
and loss of sexual interest (decreased libido) fre-
quently occur as well. Various interventions, both
non-hormonal and hormonal, are currently available
to manage these problems. The purpose of the present
review is to provide the practitioner with a wide array
of management options to assist in treating the sexual
consequences of aromatase inhibitors. The sugges-
tions in this review are based on recent literature and
on the recommendations set forth both by the North
American Menopause Association and in the clini-
cal practice guidelines of the Society of Gynaecolo-
gists and Obstetricians of Canada. The complexity
of female sexual dysfunction necessitates a bio-
psychosocial approach to assessment and manage-
ment alike, with interventions ranging from education
and lifestyle changes to sexual counselling, pelvic
floor therapies, sexual aids, medications, and dietary
supplements—all of which have been reported to have
a variable, but often successful, effect on symptom
amelioration. Although the use of specific hormone
replacement—most commonly local estrogen, and
less commonly, systemic estrogen with or without
an androgen, progesterone, or the additional of an
androgen in an estrogenized woman (or a combina-
tion)—may be highly effective, the concern remains
that in patients with estrogen-dependent breast can-
cer, including those receiving anti-estrogenic adju-
vant therapies, the use of these hormones may be
attended with potential risk. Therefore, non-hormonal
alternatives should in all cases be initially tried with
the expectation that symptomatic relief can often be
achieved.
First-line therapy for urogenital symptoms, nota-
bly vaginal dryness and dyspareunia, should be the
non-hormonal group of preparations such as moistur-
izers and precoital vaginal lubricants. In patients with
estrogen-dependent breast cancer (notably those re-
ceiving anti-estrogenic adjuvant therapies) and se-
verely symptomatic vaginal atrophy that fails to
respond to non-hormonal options, menopausal hor-
mone replacement or prescription vaginal estrogen
therapy may considered. Systemic estrogen may be
associated with risk and thus is best avoided. Judi-
cious use of hormones may be appropriate in the well-
informed patient who gives informed consent, but
given the potential risk, these agents should be pre-
scribed only after mutual agreement of the patient and
her oncologist.
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1. INTRODUCTION
With more than a million new cases and more than
400,000 deaths worldwide annually, breast cancer is
a major cause of morbidity and mortality 1. The clini-
cal efficacy of adjuvant endocrine therapies in hor-
mone-dependent breast cancer is the key to successful
intervention. However, therapeutic standards and
guidelines also emphasize that effective patient com-
pliance requires that safety and tolerability be
addressed.
Because of their greater efficacy in reducing re-
currences as well as their better tolerability profile,
the third-generation aromatase inhibitors (AIs), includ-
ing anastrozole (Arimidex: AstraZeneca, Mississauga,
ON), letrozole (Femara: Novartis Pharmaceuticals
Canada, Dorval, QC), and exemestane (Aromasin:
Pfizer Canada, Kirkland, QC), are increasingly being
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recommended as adjuvant therapy in postmenopausal
women with breast cancer. In contrast to a selective
estrogen receptor modulator such as tamoxifen, which
acts as an estrogen agonist in some tissues (for ex-
ample, bone or endometrium) and an antagonist in
others (for example, breast), AIs produce profound
suppression of estrogen in all tissues by blocking the
cytochrome P450 aromatase complex that converts
androgens to estradiol, which underlies the estrogen
receptor (ER)–positive mammary carcinogenesis 2–4.
The steroidal inhibitor exemestane, at a single oral
dose of 25 mg, leads to prolonged reduction in plasma
and urinary estrogen levels, with maximal suppres-
sion of circulating estrogens occurring 2–3 days after
dosing and persisting for 4–5 days 3. Exemestane in-
activates aromatase irreversibly, inhibiting peripheral
aromatase by 97%–98% 4. The nonsteroidal AIs—
anastrozole, at a dose of 1 mg daily, and letrozole, at
a dose of 2.5 mg daily—produce nearly 97%–99%
inhibition of estrogen biosynthesis 5,6, suppressing
total-body aromatization, plasma estrone, and estra-
diol levels in postmenopausal women with metastatic
breast cancer 5,7. Furthermore, these third-generation
AIs do not compromise glucocorticoid or mineralo-
corticoid production or thyroid function 8,9.
Tamoxifen exerts its estrogen agonist effect by
binding to the ER on endometrial epithelial and stro-
mal cells, thereby stimulating abnormal cellular pro-
liferation and increasing the risk of polyps,
hyperplasia, and endometrial cancer by a multiple of
2–4 times compared with patients not receiving
tamoxifen 10–18. Overall, nearly 10% of tamoxifen-
treated patients develop endometrial pathology within
5 years 19. Within 3 months of initiation of tamoxi-
fen therapy, significant increases in endometrial thick-
ness and in uterine volume are reported, including
endometrial cysts and polyps and growth of pre-
existing fibroids 20.
The American Society of Clinical Oncology
Technology Assessment Panel (2005) supports the
use of AIs as appropriate initial treatment for women
with contraindications to tamoxifen, or for example,
in women who develop invasive breast cancer while
taking a selective estrogen receptor modulator for
breast cancer reduction or bone loss 21. Clinical stud-
ies have clearly demonstrated the safety of steroidal
and nonsteroidal AIs from a gynecologic viewpoint.
2. AIs AND GYNECOLOGIC HEALTH
Data from the four major phase III trials of AIs, in-
cluding the Arimidex, Tamoxifen, Alone or in Com-
bination study (ATAC), MA.17, the Breast International
Group (BIG) study 1-98, and the International
Exemestane Study, have shown a lower incidence of
endometrial cancer and vaginal bleeding or discharge
with the AIs than with tamoxifen treatment 22,23.
Each of the AIs is associated with its own side
effect profile. For most women, the AI-induced
hypoestrogenic side effects are manageable. None-
theless, to appropriately address side effects, a care-
ful and comprehensive clinical evaluation needs to
be undertaken to determine which of the gynecologic
symptoms are attributable to menopause and which
are attributable to other causes.
2.1 Anastrozole (Arimidex)
Results from the ATAC trial, investigating upfront treat-
ment with anastrozole as compared with initial tamox-
ifen therapy in postmenopausal women with early
breast cancer, showed a significantly lower incidence
of hot flushes, endometrial cancer, and vaginal bleed-
ing and discharge with anastrozole 24. As well,
anastrozole was associated with significantly fewer
adverse gynecologic events in four categories 25:
• Vaginal haemorrhage with no definitive diagno-
sis: 115 vs. 186, p < 0.0001
• Leucorrhea (discharge from the vagina or uter-
ine cavity, or both): 61 vs. 218, p < 0.0001)
• Endometrial hyperplasia: 16 vs. 136, p < 0.0001
• Endometrial neoplasia: 23 vs. 118, p < 0.0001
(Distler D, on behalf of the ATAC Trialists’ Group.
Fewer gynaecological adverse events, gynaeco-
logical intervention, endometrial changes and
abnormalities with anastrozole than with tamox-
ifen: findings from the ATAC trial. Poster presented
at the 10th International St. Gallen Oncology
Conference; St. Gallen, Switzerland; March 14–
17, 2007)
Notable also was the fact that, of the patients who
experienced gynecologic adverse events, those on
anastrozole required fewer diagnostic (21.8% vs.
29.4%) and therapeutic (8.4% vs. 15.4%) interven-
tions than did those on tamoxifen. Furthermore, pa-
tients on anastrozole underwent hysterectomy at a
quarter of the frequency seen among patients on
tamoxifen [1.3% vs. 5.1%, p < 0.0001 (Distler D, on
behalf of the ATAC Trialists’ Group. Fewer gynaeco-
logical adverse events, gynaecological intervention,
endometrial changes and abnormalities with anas-
trozole than with tamoxifen: findings from the ATAC
trial. Poster presented at the 10th International
St. Gallen Oncology Conference; St. Gallen, Swit-
zerland; March 14–17, 2007)]. Most of the gyneco-
logic adverse events and endometrial abnormalities
in the ATAC trial occurred within the first 2.5 years of
tamoxifen therapy (Figure 1). The subprotocol analy-
ses also revealed both fewer endometrial abnormali-
ties and fewer medical interventions during the first
2 years with anastrozole therapy than with tamoxi-
fen 26. This finding suggests that starting postmeno-
pausal patients with early breast cancer on an AI
upfront, rather than initiating adjuvant treatment with
tamoxifen with the intention of changing to an AI after
2–3 years may be advantageous 25 (Distler D, on behalfMANAGEMENT OF SEXUAL DYSFUNCTION
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of the ATAC Trialists’ Group. Fewer gynaecological
adverse events, gynaecological intervention, endome-
trial changes and abnormalities with anastrozole than
with tamoxifen: findings from the ATAC trial. Poster
presented at the 10th International St. Gallen Oncol-
ogy Conference; St. Gallen, Switzerland; March 14–
17, 2007).
These results are consistent with findings from an
open-label randomized trial that compared, in post-
menopausal breast cancer patients, the effects of
switching to anastrozole following adjuvant tamoxi-
fen treatment (after more than 12 months, but fewer
than 48 months) with the effects of continued use of
tamoxifen, histologically confirming tamoxifen-
induced endometrial pathology (polyps, hyperplasia,
and glandulocystic atrophy) 27. The difference between
groups in recurrent vaginal bleeding [anastrozole: 4 of
83 patients (4.8%); tamoxifen: 9 of 88 patients
(10.2%)] was not significant (p = 0.18). However,
6 months later, mean endometrial thickness was sig-
nificantly less in patients who switched to anastrozole
than in those who continued tamoxifen treatment (p <
0.0001). Also, significantly fewer patients who
switched to anastrozole required repeat hysteroscopy
or dilatation and curettage as compared with patients
who continued on tamoxifen [4 of 83 patients (4.8%)
and 29 of 88 patients (33.0%) respectively; p <
0.0001) 27.
By inhibiting estrogen synthesis, the third-gen-
eration AIs reduce endometrial thickness and uterine
volume in patients previously treated with tamoxifen
(Figure 2) 20. However, patients receiving anastrozole
alone reported more vaginal dryness, painful inter-
course (dyspareunia), and loss of sexual interest, but
significantly fewer cold sweats and less vaginal dis-
charge 28,29 than did patients on tamoxifen alone.
FIGURE 1 Incidence of specific gynecologic adverse events having a lower recorded incidence with anastrozole use than with tamoxifen use
(>3% total difference), by time of occurrence in patients with an intact uterus at baseline in the Arimidex, Tamoxifen, Alone or in Combination
main trial (Distler D, on behalf of the ATAC Trialists’ Group. Fewer gynaecological adverse events, gynaecological intervention, endometrial
changes and abnormalities with anastrozole than with tamoxifen: findings from the ATAC trial. Poster presented at the 10th International
St. Gallen Oncology Conference; St. Gallen, Switzerland; March 14–17, 2007). *Patients can have an event more than once, but in different
time categories.DERZKO et al.
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2.2 Letrozole (Femara)
For patients who are intolerant to tamoxifen, switch-
ing to letrozole has been shown to reduce the fre-
quency of hot flashes 30. In the BIG 1-98 trial, patients
on letrozole experienced fewer hot flashes than did
those on tamoxifen (33.6% vs. 38.1%) 31. However,
in the MA.17 trial, letrozole was associated with a
higher incidence of hot flashes (58%) but with less
frequent vaginal bleeding than was placebo (54%) 32.
In subset analyses, women receiving letrozole expe-
rienced more bodily pain and menopausal symptoms
and a greater compromise in sexual function 33.
2.3 Exemestane (Aromasin)
As compared with tamoxifen, the steroidal aromatase
inhibitor exemestane has been shown to result in more
frequent vaginal dryness, but less vaginal discharge
and bleeding 34,35.
3. FEMALE SEXUAL DYSFUNCTION
The gynecologic signs and symptoms associated with
diminished estrogen levels, such as urogenital atro-
phy, vaginitis, dyspareunia, and loss of sexual inter-
est, may affect quality of life to varying degrees in
postmenopausal women receiving adjuvant AI therapy.
Female sexual dysfunction (FSD) is multifactorial,
involving physiologic, psychologic, social, and emo-
tional components. Delineation into four diagnostic
groups is clinically helpful 36,37:
• Hypoactive sexual desire disorder (HSDD)
• Female sexual arousal disorder (FSAD)
• Orgasmic disorder
• Sexual pain disorder
Many physiologic, psychologic, interpersonal,
and sociocultural factors may contribute to FSD
(Table I) 38. These can range from age- or illness-
related causes to results of surgical or therapeutic in-
terventions. In addition, sexual motivation and
performance can be affected by psychosexual issues.
Having breast cancer is itself an additional factor in
FSD. Breast cancer treatment may cause early and more
severe menopausal symptoms, as well as fear and
anxiety, body-image concerns, and sexual dysfunc-
tions arising from cancer treatment–induced urogeni-
tal changes.
A variety of female sex hormones, including es-
trogens, androgens, progesterone, prolactin, oxyto-
cin, and glucocorticosteroids, have been implicated
in normal female sexual function. As they interact
with neurotransmitters such as serotonin, catechola-
mines, and dopamine within the central and peripheral
FIGURE 2 Changes in double endometrial thickness (DET) from baseline to 3 months of treatment with tamoxifen and with aromatase inhibitors 20.
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nervous system, each of these hormones and their
receptors are regulated by co-activator and co-repres-
sor proteins through both endothelium-dependent and
-independent mechanisms 39. Furthermore, steroid
hormones can be produced within cells in peripheral
target tissues and remain there. Although these hor-
mones are not found within the systemic circulation,
they are believed to exert an important local effect—
a process called intracrinology 40. The specific roles
of these individual hormones in sexual responsive-
ness have been difficult to identify clearly.
3.1 Clinical Assessment of FSD
Complaints of sexual dissatisfaction or dysfunction
in postmenopausal women merit thorough evaluation:
• A sexual history is critical, and self-report ques-
tionnaires (see Appendix A) can also be used to
assist with the assessment 41–43. General, medi-
cal, surgical, psychiatric, psychosexual, and re-
lationship factors should be evaluated.
• Physical examination, including a gynecologic
examination, should be done.
• Hormonal evaluation may also be indicated, be-
cause levels of a number of relevant hormones
may be altered in women on AIs 44.
Unquestionably, local (vaginal) factors should be
addressed in AI-treated women, as well as in all
women with sexual difficulties. If local factors are
deemed to be an issue, local treatment with vaginal
moisturizers and precoital lubricants should be initi-
ated. If vaginal dryness or lack of elasticity with re-
sulting dyspareunia persist, and if the resulting sexual
dysfunction is distressing to the patient, local treat-
ment with vaginal estrogens may be considered. Con-
sideration of systemic estrogen therapies, rarely
indicated for vaginal complaints, should be reserved
for those women whose severe and distressing sys-
temic symptoms (for example, severe vasomotor dis-
turbances) fail to respond to non-hormonal therapies
(for example, clonidine, selective serotonin reuptake
inhibitors, selective norepinephrine reuptake inhibi-
tors). Consultation with the patient’s oncologist
should precede initiation of hormonal therapy.
3.1.1 The Sexual History
Obtaining a detailed sexual history is not only criti-
cal to addressing appropriate sexual concerns, it is
also therapeutic in itself. Faced with a life-threaten-
ing disease, women with breast cancer may feel that
their altered sexuality is not a medically legitimate
complaint, or that their health care professionals view
sexual changes as irrelevant to other issues or are
uncomfortable addressing sexual issues. However,
sexual dysfunction is well known to interfere with
both quality of life and the recognized need for inti-
macy during cancer diagnosis and treatment. It is
therefore important to include questions that address
the possibility of sexual concerns. (For example,
“Many women with your diagnosis have sexual con-
cerns. Do you? Many patients may be reluctant to
mention it themselves.”) Sexual histories should be
taken in the context of current medications and stage
of cancer treatment. Cancer treatments and reduced
TABLE I Factors underlying female sexual dysfunction 38
A. Physiologic factors
1. Aging and menopause
Normative and gradual decline in desire; decreased
genital perfusion, engorgement, and vaginal lubrication,
touch perception, and vibratory sensation; decreased
muscle tension in the pelvic floor, and decreased uterine
contractions during orgasm
2. Endocrine changes
Low estrogen levels leading to vaginal dryness, pain
during vaginal penetration, and dyspareunia; low
androgen levels linked to decreased sexual desire, genital
sensation, and genital response
3. Sickness, injury, or disability
Neurovascular injury related to (for example) cardiovas-
cular events, arthritis, diabetes mellitus, and pain; limited
mobility related to other medical conditions
4. Surgical therapies
Surgical menopause, oophorectomy, hysterectomy;
postsurgical dyspareunia or orgasmic dysfunction, or
damage to pelvic nerves during presurgical procedures
5. Prescription medications
Antidepressants (especially selective serotonin reuptake
inhibitors and dopamine receptor blockers); central
nervous system depressants and estrogen, androgen, or
cholinergic antagonists; antihypertensive medications
(centrally acting sympatholytic agents, beta-blockers,
diuretics)
B. Psychologic factors
Defective physical or mental status
History of physical or sexual abuse
Poor self esteem or self-image
Unrealistic goals (long-term relationship and getting older)
Stress and performance anxiety
Sexual inexperience or inadequacy
Conflicting gender or sexual orientation
C. Interpersonal factors
Lack of partner
Perceived unattractiveness
Fastidiousness with nonsexual aspects
Interpersonal conflicts
Lack of desire
Inadequate foreplay or poor technical skill
Obsession with intercourse
Rushing toward orgasm
Communication problem with needs and preferences
Sexual dysfunctions of the partner
No time for adventure; predictable or boring sexual routine
Privacy issues
D. Sociocultural factors
Inadequate sex education
Antagonistic religious or family values
Cultural taboos
Gender discriminationDERZKO et al.
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hormone levels may result in lowered mood, fatigue,
and loss of sexual interest not only because of the
aforementioned stressors, but also because of a re-
duction in sexually satisfying experiences as a result
of dyspareunia or other gynecologic effects of can-
cer treatment.
History-taking in regard to each sexual concern
should include
• delineation of the concern (interest, arousal, or-
gasm, pain);
• appraisal of precipitating factors and duration of
the concern;
• evaluation of whether the sexual concern arises
only in some situations or is generalized in its
presentation;
• description of the concern (how and when the
concern appears and how it plays out in sexual
situations);
• assessment of whether the sexual concern affects
another aspect of sexual response (that is, low
sexual drive may precipitate arousal or orgasmic
disorders);
• determination of whether the partner has sexual
concerns that may contribute to the woman’s
sexual dissatisfaction;
• review of the sexual context within which the
woman participates (that is, frequency of sexual
activity or attempts, effectiveness of sexual tech-
niques, quality of personal relationship with part-
ner, self and partner expectations); and
• appraisal of previous therapies for the sexual con-
cerns under discussion and the motivation to pur-
sue symptomatic relief.
With any sexual dysfunction, assessing the re-
sulting degree of personal distress while evaluating
the patient for physical, psychosocial, organic, and
biologic aberrations is important 45. Screening for
depression, chronic illness, or therapy causing adre-
nal suppression is essential. In regard to the latter,
results from a randomized double-blind multicentre
trial indicate that AIs such as oral letrozole at daily
doses of 0.5 mg and 2.5 mg suppressed estrogen lev-
els at both doses without affecting adrenal activity in
postmenopausal advanced breast cancer patients pro-
gressing after tamoxifen 9.
Finally, from a medical viewpoint, sexuality en-
compasses more than genital functioning. Bladder
and bowel issues, altered genital sensation, mobility
limitations, pain from concomitant medical condi-
tions, presence of a non-cancer-related chronic ill-
ness, fatigue, use of medications other than those
for cancer, sexual self-image and self-esteem, part-
nership, motherhood, and parenting issues all affect
the sense of sexual self and sexual functioning 46. It
is advisable to ask patients questions about these is-
sues. The next subsection illustrates an approach that
can be used.
3.1.2 Physical Examination for FSD
General assessment should include thyroid status;
cardiovascular, musculoskeletal, and neurologic pa-
rameters; breast examination for further pathology
or hyperprolactinemia (nipple discharge); and signs
of anemia.
A complete gynaecologic assessment should en-
compass these possible sources of sexual difficul-
ties 42,47:
• Vulvovaginal estratrophy (introital narrowing,
vaginal pallor, dryness, loss of rugosity, friability)
• Abnormal discharge (bubbly, cheesy, foul-smelling)
• Vaginal or perineal lesions (for example, condy-
lomata acuminata, herpes, trauma)
• Size and elasticity of introitus (any atrophy, le-
sions, scarring, or strictures)
• Discharge or evidence of infection, vulvodynia,
and deep tenderness
• Sparse hair of the mons pubis (may suggest low
androgen levels)
• Vulvar skin lesions indicating possible infection
(Candida, herpes), dermatitis (eczema, psoriasis,
allergic reaction), or dermatoses (lichens)
• Atrophy, lesions, or adhesions of the labia ma-
jora and minora
• Phimosis and adhesions of the clitoris and female
genital surgery (including circumcision)
• Infection or prolapse of the urethra
• Vulvovestibulitis of the vulva and bulbourethral
glands (by swab)
• Possible cystocele, rectocele, uterine prolapse, or
urinary incontinence (Valsalva manoeuvre)
• Pain or masses (internal bimanual examination)
or problems with vaginal tissues and cervix
(speculum examination)
Impaired vaginal and rectal muscle tone, pelvic
floor hypertonicity, or poor or absent bulbocavernosal
reflex may suggest possible sources of sexual
difficulty.
Table II lists suggested biochemical investiga-
tions 45. Drugs such as AIs that block ovarian func-
tion effectively reduce androgen levels. Finding a low
serum testosterone level is neither diagnostic nor pre-
dictive of sexual dysfunction. Thus, it is generally
agreed that serum testosterone determinations should
not be used to make a diagnosis. The major role of
testosterone determination is in monitoring testoster-
one therapy to ensure that testosterone levels remain
within the acceptable normal range 48. Although an-
drogens decline with age in all women, no consen-
sus yet exists on normal age-related levels, because
large numbers of control and dysfunctional popula-
tions alike need to be screened for levels of andro-
gens and their metabolites. Another challenge is the
development of a reliable assay specifically for the
lower levels of testosterone found in women 49. The
current view is that the total testosterone assay, whichMANAGEMENT OF SEXUAL DYSFUNCTION
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measures both freely circulating testosterone and the
portion bound to protein, is inaccurate for women
with lower ranges of serum testosterone 49. In the
Canadian context, levels of free testosterone (not
bound to sex-hormone globulin) and bioavailable
testosterone (free testosterone and testosterone
loosely bound to albumin) are considered more in-
dicative of cellular or bioactive status than is the total
testosterone level. However, the concept of intra-
crinology mentioned earlier further confuses the pic-
ture. The U.S. Endocrine Society has recommended
that, until a well-defined clinical syndrome and nor-
mative data on total or free testosterone levels across
the lifespan have been established, a diagnosis of
“androgen deficiency” in women should not be made
on the basis of serum testosterone levels 50.
In summary, there are four significant challenges
to the concept of androgen deficiency in women 50:
• Testosterone assays are inaccurate, and their re-
sults are difficult to interpret.
• The correlation between measured low serum
testosterone levels and HSDD libido is at best cat-
egorized as “fair.”
• Low serum testosterone levels are rarely the cause
of HSDD; nonetheless, it remains possible that treat-
ment with testosterone in women with low de-
sire may prove beneficial for responsive sexual
drive and may possibly alter orgasmic attainment
if endogenous androgen levels are significantly
reduced by cancer treatments.
• Aromatization of androgens by adipose tissue is
a concern in women with a history of breast can-
cer, because androgen administration may affect
the plasma and cellular concentrations of estro-
gens 51.
In the absence of specific guidelines or data re-
garding the prescription of testosterone without es-
trogen or the absence of any long-term safety or
efficacy data and the inability to unequivocally de-
termine androgen deficiency in women with acquired
sexual dysfunction, the SOGC recommends that clini-
cians should exercise caution and seek the patient’s
informed consent when initiating testosterone treat-
ment 43. This partnership approach is particularly
important for breast cancer patients, because, nota-
bly, concerns still surround the immediate and long-
term safety issues related to aromatization of
androgens to estrogen for women with breast cancer.
4. APPROACH TO MANAGEMENT OF
SEXUAL DYSFUNCTIONS
The multifactorial nature of female sexual concerns
defies a quick fix; therapeutic interventions should
be tailored to address each area of distress (psycho-
logic, interpersonal, sociocultural, and physiologic)
and to attend to each affected functional domain (de-
sire, arousal, orgasm, pain).
Available modalities range from education, coun-
selling, and lifestyle interventions to mechanical de-
vices, pelvic floor exercises, and medications 38.
Summaries of therapeutic approaches to the various
aspects of sexuality follow. Pharmaceutical interven-
tions are subsequently discussed.
4.1 Sexual Disinterest
Women should be advised that an age-related low-
ered spontaneous (that is, biologically driven urge)
sex drive is not abnormal. It is important that breast
cancer patients, including those on AI therapy, be made
aware of this fact. Although women may choose to
be sexual in answer to a biologic sexual urge, they
may also be motivated to be sexual for reasons other
than sexual drive (generation of emotional closeness,
reassurance of a loving relationship despite a diag-
nosis of cancer or a disfigurement, partner satisfac-
tion, and so on). Although these behaviours are quite
normal, it is equally important not to pathologize dis-
inclination to engage in sexual behaviour unless that
disinclination is distressing to the woman, because
her response may be adaptive rather than dysfunc-
tional 52.
Various models have been used to describe the
female sexual response 53–55. These include the linear
model described by Masters and Johnson, whereby
genital arousal builds and culminates in orgasm 53; a
single normative (spontaneous urge) responsive pat-
tern driven by sexual desire leading to arousal and
orgasm 54; and a circular model, whereby arousal and
responsive drive may not be driven primarily by urge
but by other motives, such as intimacy need 55. In a
large community sample of nurses with and without
sexual concerns who were asked to endorse one
model that best described their sexuality, all models
were endorsed equally, demonstrating the heteroge-
neity of female sexual response; however, the women
who endorsed the circular model tended to be women
whose sexual experiences were more problematic and
unsatisfying (that is, women with lower Female
TABLE II Basic biochemical investigations for women presenting
with low libido 45
General
Thyroid-stimulating hormone, iron stores
Specific
Estradiol + follicle-stimulating hormone (for diagnosis of
hypothalamic amenorrhea or premature ovarian failure)
Prolactin
Sex hormone binding globulin (SHBG)
Free testosterone and bioavailable testosterone
Calculated free androgen index: Total testosterone (ng/L) /
SHBG (ng/L) × 100, if SHBG is in normal range
Dehydroepiandrostenedione (DHEA-S)
Early morning cortisol if adrenal insufficiency suspectedDERZKO et al.
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Sexual Function Index scores and those who reported
more dissatisfaction with their emotional relationship
with their partner) 56. Thus, a woman’s past sexual
experience and present sexual context is important
in determining her current sexual life expectations.
In assessing sexual concerns, the key elements to dis-
cover are what has changed or what is missing (or
both), how satisfying current sexual experiences are,
and how distressed the woman is about the changes
(that is, what the consequences of current circum-
stances are). Medically, it is important to seek out
and address any potentially reversible causes (that
is, dyspareunia, depression, hormonal alterations,
medication use) and to retain lifestyle and counsel-
ling assistance with adaptation to the changes if they
persist. Cognitive behavioural therapy and other psy-
chological interventions are often used clinically in
the management of low desire, but outcome studies
are few to date.
4.2 Sexual Arousal and Orgasmic Problems
Arousal problems may stem from inadequate physi-
ologic support to allow for proper vasocongestion,
inadequate mental and physical sexual stimulation,
or distracting factors such as stress or fear of pain or
of bladder incontinence. (See mitigation suggestions
later in this subsection.)
Vaginal dryness during sexual activity can be
treated symptomatically with commercial lubricants.
Various products are available, and most women pre-
fer an odourless, non-irritating preparation. To avoid
staining bed sheets or clothing, water-based lubri-
cants should be used with latex condoms. Patients
could try thin, water-based lubricants such as
Astroglide (Biofilm, Vista, CA, U.S.A.) or KY Liq-
uid (KY, Guelph, ON), or glycerine-free water-based
lubricants such as Slippery Stuff (Wal-Med,
Puyallup, WA, U.S.A.), Liquid Silk and Maximus
Liquid Silk (Bodywise, Cowes, U.K.), Sliquid
(Sliquid LLC, Dallas, TX, U.S.A.), and Hathor
Aphrodesia (Hathor Skin Care, Vancouver, BC),
because these products are less likely to cause aller-
gic reactions. The patient—and her partner—should
be encouraged to check for new products available
in their pharmacy.
Increased intensity and duration of genital (es-
pecially clitoral) stimulation may be required for
arousal and orgasm. Sometimes couples sexual
therapy to instigate better understanding of the
woman’s needs may allow for improved partner tech-
nique. High intensity vibrators for self or partnered
sexual activity have proven successful in allowing
some women to obtain more stimulation than can be
achieved by intercourse or hand or oral stimulation
alone, especially when placed directly on or near the
clitoris, or even intravaginally 57. Several can be dis-
creetly purchased from Web-based companies. The
Eros Clitoral Therapy Device (UroMetrics, St. Paul,
MN, U.S.A.), a small clitoral vacuum pump used for
women with and without FSAD to increase sensation,
vaginal lubrication, orgasmic attainment, and greater
overall sexual satisfaction, has been approved by the
U.S. Food and Drug Administration (FDA). In select
women, it may be beneficial.
Well-controlled randomized trials of psychoso-
cial intervention for FSAD in women with cancer are
lacking. Recently, however, Brotto and colleagues
used a brief, three-session psycho-educational inter-
vention (PED) in 22 women with early-stage gyneco-
logic cancer who had FSAD and found a significant
positive effect of the PED on sexual desire, arousal,
orgasmic satisfaction, sexual distress, depression, and
overall wellbeing, and a trend toward significantly
improved physiologic genital arousal and perceived
genital arousal 58.
4.3 Pelvic Floor Exercises for Sexual Pain Disorders
The pelvic floor is innervated by the limbic system
and is highly reactive to emotional stimuli; pelvic
floor therapies may therefore be effective in dyspareu-
nia. A six-member committee focusing on women’s
sexual pain disorders, part of an international con-
sultation of more than 200 multidisciplinary experts
from 60 countries, found that distinguishing vaginis-
mus from dyspareunia may be difficult using clinical
tools. However, physical therapists can differentiate
vaginismic women from matched controls based on
muscle tone and strength differences. The commit-
tee recommended a revision to the definitions of
vaginismus and dyspareunia, integration of treatment
approaches, validation of non-specific treatment ef-
fects, controlled studies to test interventions, and sex
education to help prevent sexual pain 59. Learned re-
laxation of the pelvic floor may assist women who
experience pain from hypertonicity, provided that the
primary reason for the increased tone is identified. In
women without pain, improvement of pelvic floor
tone and enhancement of orgasm may be achieved
through the practice of pelvic floor exercises, includ-
ing Kegel exercises.
4.4 Bladder and Bowel Issues
Discomfort from urinary tract infections, fear of urine
leakage with orgasm, and stress incontinence can in-
terfere with sexuality. Based on clinical studies that
showed reduced vaginal pH and increased lacto-
bacilli following treatment, the SOGC guidelines rec-
ommend intravaginal estrogen in postmenopausal
women to prevent urinary tract infections associated
with aging 60. The previously noted precautions on
hormone therapy should be kept in mind when ap-
plying these recommendations to women who have
been diagnosed with breast cancer.
Bowel constipation and flatulence or diarrhea
secondary to medications, alteration in eating patterns,MANAGEMENT OF SEXUAL DYSFUNCTION
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or radiation treatments will also dissuade sexual ac-
tivity. Alleviation of bladder and bowel symptoms
and anxieties can be helpful sexually.
4.5 Mobility Challenges and Sensory Alterations
Women with joint pain may have difficulties with
thigh abduction for intercourse or may not be able to
withstand pelvic or hip pressure from the weight of
their partners. The use of analgesics before activity
and the use of cushioning and supports for comfort-
able sexual positioning can be helpful. Also, genital
sensitivity may decrease with neurogenic changes of
age and lowered testosterone levels, with arousal re-
quiring longer and more direct genital stimulation. It
is important that adequate lubrication be present to
reduce friction irritability of the genital tissues.
4.6 Management of Concomitant Medical
Conditions and Non-genital Menopausal
Symptoms
Many medications and drug therapies prescribed to
treat medical conditions are associated with sexual
dysfunction as a result of associated vascular and
psychoneuroendocrine mechanisms. A comprehen-
sive assessment of sexual function before and with
current antihypertensive, psychopharmacologic, or
other medication-based treatment is therefore man-
datory 61. Because many postmenopausal women may
have pre-existing pain or soreness, diabetes, or ar-
thritis, they may find it desirable to maximize pain
control with analgesics and to enhance mental and
muscular relaxation before engaging in sexual activ-
ity. Other suggestions may include taking a warm
bath, planning for times of lowest fatigue, emptying
the bladder, and taking quiet time to remove stres-
sors before engaging in a sexual activity.
Menopausal symptoms can be managed in the
same way in women using AIs as in women without
breast cancer. However, as noted earlier, because of
potential risks, the use of any hormone replacement
treatment requires both special consideration and
caution. Menopausal symptoms, particularly hot
flashes, are reported more often and are considered
to be more distressing, severe, and longer in duration
in women with breast cancer 62. Therapeutic options
for the management of hot flashes in breast cancer
survivors include centrally acting agents (for example,
venlafaxine, paroxetine, gabapentin, clonidine). Use
of non-pharmacologic and complementary or alter-
native therapies (soy phytoestrogens, black cohosh,
and vitamin E) cannot safely be recommended be-
cause of a lack of quality evidence (level I or level II)
of either efficacy or of short or long-term safety data
on which to base such recommendations. Further-
more, various reports have been surfacing of inaccu-
rate labelling—active ingredients present despite label
claims to the contrary—in many such store-bought
products. These “natural” products are not under the
same regulatory governmental control as are phar-
maceuticals 62.
4.7 Sexual Self-esteem and Self-image
Breast surgery, depending on the type and extent, can
affect body image and self-esteem, and the issues of
body image and sexuality after breast cancer may
become increasingly important with time elapsed
since surgery 63. Mastectomy patients have a signifi-
cantly poorer body image and lowered scores for fe-
male role and sexual function as compared with
patients who undergo breast-conservative surgery 64.
The vulnerability of both body image and sexuality
is greater in patients with advanced breast cancer and
in those who need adjuvant treatment, have lymphe-
dema, are sedentary, have poor family and social sup-
ports, or are single or in an unstable relationship.
Sexual or psychological counselling, or both, are rec-
ommended for breast cancer survivors and their part-
ners so as to improve the quality of intimacy and body
image 63.
Not to be forgotten is the physical discomfort and
pain arising from mastectomy or breast surgery it-
self. When felt during intercourse or love-making,
this symptom may be upsetting to both the woman
with breast cancer and her partner. If the incision or
muscles are tender, the patient can minimize the pres-
sure on the chest area by lying on the unaffected side.
This position provides the patient with more control
over her movements, reducing irritation to the inci-
sion. If the partner is on top, the patient can be ad-
vised to protect the affected area by putting a hand
under her chin, with her arm against her chest. If she
feels any pain, she should stop and let her partner
know why she is stopping. If the couple have dis-
cussed this problem in advance and have clarified
that the cancer patient will speak up when she no-
tices any pain, then both will feel more relaxed and
less inhibited in exploring and experimenting. Tak-
ing a rest or changing position may also help the can-
cer patient to relax, which may in itself reduce pain.
Such a pause also provides an opportunity to apply
extra lubrication. With communication and coopera-
tion, the patient and her partner can work together to
find positions and activities that give the most plea-
sure 65.
4.8 Relationship Concerns
Sexual life can be altered significantly with the
changed relationship dynamics that may accompany
diagnosis and treatment of cancer. Psychosexual
therapy for the patient alone or with her partner may
ameliorate specific psychologic or interpersonal fac-
tors such as relationship distress, extended periods
of sexual abstinence, and dysfunctional communica-
tion patterns—possibly enhancing sexuality 66.DERZKO et al.
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5. PHARMACOLOGIC THERAPIES FOR FSD
The principles for managing symptoms in women
with breast cancer follow the strategies seen in the
care of postmenopausal patients with sexual health
problems 66. Multidisciplinary interventions must be
considered as needed, and modification of reversible
causes includes sex therapy, lubricants, altering medi-
cations, modifications in lifestyle, and physical
therapy for pelvic floor disorders. At that point, first-
line therapies should be administered upon diagno-
sis, and after needs, expectations, risks, benefits, and
costs have been clarified. More invasive second-line
therapies are initiated only with failures or insuffi-
cient response 66.
5.1 HSDD
Data suggest that estrogen-deficient postmenopausal
women experience an increased incidence of sexual
dysfunction and that estrogen or estrogen–progestin
therapy (ET/EPT) may improve or correct the problem
(Figure 3) 67,68.
Although the benefits and risks of hormone
therapy in 50- to 80-year-old “normal/healthy”
women (that is, without breast cancer) continue to
be debated, the Women’s Health Initiative 69 provided
no information about the risks of ET/EPT use in meno-
pausal women with breast cancer. However, two in-
dependent randomized controlled trials begun in 1997
studied the question of hormone replacement therapy
(HRT) following a diagnosis of breast cancer, and they
reached two diametrically opposed conclusions. The
HABITS (Hormonal Replacement Therapy—Is It Safe?)
trial was stopped after a median of just 2.1 years be-
cause of a statistically significantly higher recurrence
of breast cancer in the treated group [relative risk (RR):
3.3; 95% confidence interval (CI): 1.5 to 7.4] 70. How-
ever, the Stockholm Randomized Trial found no sig-
nificant increase in breast cancer in the treated group
at a median of 4.1 years (RR: 0.82; 95% CI: 0.35 to
1.9) 71.
Low-dose, local vaginal estrogen therapy
[Premarin cream (Wyeth Pharmaceuticals, Philadel-
phia, PA, U.S.A.), Vagifem tablets (Novo Nordisk,
Princeton, NJ, U.S.A.), Estring (Pfizer Canada), or if
available, the more poorly absorbed estriol vaginal
cream] is not uncommonly prescribed and may be
considered (with the permission of the oncologist)
for highly symptomatic ER-positive early breast can-
cer patients who are unresponsive to non-hormonal
therapy. However, a decision to use systemic hor-
mone therapy must be undertaken with considerable
caution.
Given the uncertainty of the reason for the dis-
cordant conclusions of the HABITS and Stockholm tri-
als, despite the efficacy and numerous benefits of
ET/EPT demonstrated in the early, otherwise healthy,
menopausal woman, a decision to use systemic meno-
pausal hormone therapy in a woman with early breast
cancer should be made only after careful consider-
ation of the alternatives and consultation with the
entire treatment team—including the patient.
In the absence of a biochemical measure that
clearly identifies who can be treated, the Endocrine
Aspects of Female Sexual Dysfunction Committee
suggests that exogenous testosterone should be con-
sidered only after other causes of HSDD such as de-
pression, relationship problems, and ill health have
been excluded. The Committee recommends com-
prehensive risk–benefit analysis and informed con-
sent of patients before therapeutic management of
HSDD with hormonal therapies is contemplated (sum-
mary in Table III) 45.
A 2005 position statement from the North Ameri-
can Menopause Society (NAMS) indicates that post-
menopausal women may be candidates for
testosterone therapy if they present with symptoms
of decreased sexual desire associated with personal
distress and if they have no other identifiable cause
for their sexual concerns 48. Testosterone therapy is
not recommended in the absence of concomitant es-
trogen therapy, because data on the safety and effi-
cacy of testosterone therapy in women not using
FIGURE 3 Association between lower estrogen levels and increased prevalence of sexual problems 67,68.MANAGEMENT OF SEXUAL DYSFUNCTION
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concomitant estrogen are lacking. Another NAMS rec-
ommendation is that postmenopausal women undergo
laboratory testing for testosterone levels only to moni-
tor for supraphysiologic levels before and during
therapy 48. As noted earlier, any hormonal therapy in
the patient treated for breast cancer must be under-
taken only with extreme caution.
5.2 Androgen Therapies and Breast Cancer
A net decline in testosterone levels occurs following
natural menopause. In the premenopausal female, 50%
of the circulatory levels of testosterone represent equal
contributions from the ovaries and the adrenal glands,
but with increasing age, the contributions of the adre-
nal glands, the peripheral tissue, and the ovaries to
dehydroepiandrosterone (DHEA) sulphate remain about
the same, while the contribution of the ovaries to the
testosterone pool increases significantly. Nevertheless,
overall levels of androgen decrease because of the
precipitous decline in production of testosterone pro-
hormones from the adrenal gland—to the extent that
the ovaries cannot correct the deficit 72. The symp-
toms of low androgen in women are reported to be
similar to those in men: a decrease in libido, energy,
or sense of wellbeing, and decreased lubrication and
arousability even in the presence of estrogens 73. In
the absence of estrogen, and after aromatase conver-
sion, androgens elicit an ER-mediated stimulation.
Few studies exist to confirm the benefit of inter-
vention with androgens in breast cancer patients or
in postmenopausal women at increased risk for the
disease. In one study, during a mean follow-up of
5.8 years, no increase in breast cancer was seen in a
group of postmenopausal women when testosterone
was added to HRT 74. A prospective, double-blind study
investigated the use of a transdermal nicotine patch
(300 mg daily) in postmenopausal women, together
with continuous combined estradiol 2 mg and norethi-
sterone acetate 1 mg and randomized additional treat-
ment with either a testosterone or a placebo patch in
equal numbers 75. The findings indicated that the ad-
dition of testosterone to a common estrogen–
progestogen regimen inhibits the stimulatory effects
of hormones on breast cell proliferation 76.
In a randomized placebo-controlled study inves-
tigating DHEA 50 mg daily over a period of 12 months,
a significant increase in sexual satisfaction and a pos-
sible increase in sexual interest and activity was dem-
onstrated in older (ages 70–79 years), but not younger
(ages 60–69 years) women 77. In the absence of any
long-term studies with DHEA, a risk of ultimate
aromatisation to estrogen may have gone undetec-
ted, especially in patients already receiving AIs for
breast cancer. However, one author suggests that “the
fear that testosterone [will] be aromatised to estro-
gen is more paranoia than reality” considering the
low levels of conversion to estrone and estradiol that
make any risk of breast cancer extremely unlikely 73.
Furthermore, testosterone has been used off-label,
without serious safety problems, in postmenopausal
women for decades to the benefit of properly selected
subjects. Nonetheless, inconclusive results and sig-
nificant methodologic limitations pertaining to the use
of testosterone leave the evidence with regard to
breast cancer risk uncertain 78, and therefore testoster-
one is not currently recommended for women with
breast cancer. Discussion is required before treating
this patient population with testosterone therapy.
A recent randomized placebo-controlled phase III
crossover clinical trial randomly assigned
150 partnered postmenopausal women with a history
of cancer who were reporting a decrease in sexual de-
sire to a 10-mg equivalent testosterone dose in a cream
base [Vanicream (PSI, Rochester, MN, U.S.A.), 2%
testosterone] or placebo for 4 weeks each. It was dem-
onstrated that women who were on active testoster-
one cream had higher serum levels of bioavailable
testosterone than did the women on placebo, but the
average intra-patient libido change from baseline to
weeks 4 and 8 was similar in both arms 79. No adverse
effects on estrogen levels or liver function were noted
in this short-term study. The authors suggested that
the increased testosterone level did not translate into
improved libido possibly because women in the study
were estrogen-depleted. In addition to the possible
significance of the placebo effect in this study, the
study’s null results highlight the complex relationship
of biologic, emotional, and cognitive inputs to the
perception of desire 80 and still provide no informa-
tion about long-term safety of androgen use in women.
The FDA has already requested more long-term safety
data on the testosterone patch Intrinsa (Procter &
TABLE  III Systemic hormonal therapies for management of
hypoactive sexual desire disorder 45
Vaginal estrogen preparations improve vaginal lubrication and
reduce dyspareunia and urogenital atrophy.
Systemic estrogen or estrogen–progestogen therapy assists with
vasomotor and other menopausal symptoms.
Use of estrogen with or without progestogen therapy after breast
cancer is indicated only for women with moderate to severe
symptoms under informed patient consent and with careful
monitoring for cardiovascular, thrombotic, and breast cancer
risks.
Transdermal delivery of testosterone and its derivatives for
temporary increase in libido, arousal, and orgasm in
postmenopausal women already treated with systemic
estrogen.
Testosterone therapy exceeding 6 months is indicated only if
sexual function improves.
Patients with a family history of diabetes or significant obesity
should be monitored for lipid profile and fasting insulin and
glucose levels while on hormonal therapies.
Tibolone may be an alternative to estrogen–androgen therapies
for treating postmenopausal sexual dysfunction.DERZKO et al.
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Gamble Pharmaceuticals, Egham, U.K.) for medical
treatment of FSD in menopausal women.
Although naturally postmenopausal women with
symptoms of testosterone deficiency despite con-
ventional hormone therapy may benefit from andro-
gen treatment, studies have yet to be done to see
this benefit in cancer survivors. Any long-term tes-
tosterone therapy requires close monitoring for skin
and hair problems, including seborrhea, acne, hir-
sutism, and androgenic alopecia, and for voice
changes. Monitoring for biochemical changes and
for free and bioavailable testosterone levels and sex-
hormone binding globulin is desirable 45.
5.3 Phosphodiesterase Inhibitors for FSAD
Phosphodiesterase V inhibitors (PDE5Is) work
through the nitric oxide–cyclic guanosine monophos-
phate pathway to relax genital cavernosal smooth
muscle in erectile tissues in both men and women
following sexual arousal. The PDE5Is currently used
for the treatment of erectile dysfunction in men in-
clude sildenafil (Viagra: Pfizer Canada), vardenafil
(Levitra: Bayer, Toronto, ON), and tadalafil (Cialis:
Eli Lilly and Company, Toronto, ON). For aroused
women, PDE5Is induced tumescence of the smaller
erectile structures, which may or may not make a
difference to subjective sexual response. Sildenafil
(50 mg, adjustable to 100 mg or 25 mg) has been
shown to increase vaginal lubrication, genital sen-
sation, ability to achieve orgasm, and overall satis-
faction in a 12-week double-blind placebo-controlled
study in 202 postmenopausal women with FSAD with-
out concomitant HSDD or contributory emotional, re-
lationship, or historical abuse issues 81. In another
study using a modelling and simulation framework
based on telephone sexual activity diary data, a dose-
dependent effect was observed with sildenafil cit-
rate in patients with FSAD 82. However, in a large,
multicentre, placebo-controlled trial examining the
efficacy and safety of sildenafil 10–100 mg taken
1 hour before sexual activity in two groups of women
(estrogen-replete, n = 577; estrogen-deficient, n =
204) with FSAD, no increase in sexual arousal was
noted at any treatment dose. In addition, side effects
included headache, flushing, rhinitis, nausea, visual
disturbance, and dyspepsia 83.
Large, long-term clinical trials to firmly estab-
lish the efficacy and safety of these drugs in women
have not yet been carried out as they have been in
men. But a randomized controlled trial using the tech-
nique of vaginal photoplethysmography to study geni-
tal vasocongestion demonstrated reduced latency to
orgasm in a subgroup of postmenopausal women with
acquired genital FSAD who were taking sildenafil 84.
There are also studies showing that sildenafil can re-
verse antidepressant-induced FSAD 85. However,
sildenafil is contraindicated for women with recent
myocardial infarction or stroke, active coronary is-
chemia, or episodes of heart failure, and in those re-
ceiving nitrates 86.
Topical prostaglandin E1 (alprostadil) works dif-
ferently than PDE5Is do, directly relaxing erectile
smooth muscle through the cyclic adenosine mono-
phosphate system and therefore not requiring nitric
oxide release from the nerve endings (that is, sexual
arousal) to work. In men, prostaglandin E1 is highly
effective in intracavernosal penile injection therapy,
but less successful when used as an intraurethral sup-
pository or as a penile topical application for erectile
dysfunction. Preliminary studies in postmenopausal
women with FSAD indicate that, as compared with pla-
cebo, topical application of alprostadil to the genita-
lia in doses of 400 mg produced reports of significantly
greater physical and emotional arousal and sexual sat-
isfaction 87; however, these results have been incon-
sistent and not reproducible in other trials 88. The
results of ongoing clinical studies are needed to fur-
ther define the role of topical alprostadil in the treat-
ment of FSAD.
5.4 Bupropion for Sexual Desire, Arousal, Orgasm,
and Satisfaction
Sustained-release bupropion (Wellbutrin SR:
GlaxoSmithKline, Mississauga, ON) 300 mg daily
used for 4 weeks has been shown to increase sexual
desire and frequency of sexual activity in patients
with antidepressant-induced sexual dysfunction, as
measured by the Changes in Sexual Functioning
Questionnaire 89. However, in non-depressed pre-
menopausal women, bupropion significantly in-
creased sexual arousal, orgasm completion, and
sexual satisfaction, but not desire 90. In depressed
women, extra-long-release bupropion (Wellbutrin
XL) 300 mg daily was found not to change sex func-
tioning scores and had the same antidepressant ef-
fect as venlafaxine XR, but without the adverse
effects on sexual function of the latter medication 91.
Bupropion can also be added to an antidepressant
regimen to attempt to ameliorate some induced side
effects. Further studies are needed in view of the
risk of seizures, especially in women with eating
disorders.
5.5 Alternative Therapies
A number of dietary supplements have been investi-
gated for the treatment of FSD. Nutritional supplements
containing ginseng, ginkgo, L-arginine, damiana, vi-
tamins, and minerals have also been reported to im-
prove sexual desire, vaginal dryness, clitoral sensation,
and frequency of sexual activity in normal female
volunteers 92, but not in women with cancer or receiv-
ing AI therapy.
Meanwhile, researchers are exploring the efficacy
and safety of the dopaminergic agonist apomorphine
(sublingual, intranasal) and of melanocortin-stimulatingMANAGEMENT OF SEXUAL DYSFUNCTION
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hormone (intranasal) in the treatment of HSDD. For
FSAD, studies are underway into selected vascular
smooth muscle relaxants, including nitric oxide path-
way agents such as arginine and the prostaglandin E1
topical cream described earlier 93,94.
6. GYNECOLOGIC MANAGEMENT OF
SEXUAL PAIN FROM ATROPHIC VAGINITIS
AND VAGINAL ATROPHY
Approximately 40% of postmenopausal women have
symptoms of atrophic vaginitis, and yet fewer than
25% of them seek medical help. Although the condi-
tion is attributable to estrogen deficiency, anti-estro-
genic medications such as tamoxifen (and possibly
AIs) or medical or surgical conditions that result in
decreased levels of estrogen can exacerbate the signs
of decreased vaginal lubrication, followed by other
vaginal and urinary symptoms aside from concomi-
tant infection (Table IV) 95.
As the vaginal mucosa becomes thinner and drier
because of declining estradiol levels (from 120 ng/L
at perimenopause to about 18 ng/L after menopause),
vaginal discomfort, dryness, burning, itching, and
dyspareunia may occur and usually progress with
time. Inflammation of the vaginal epithelium may
contribute to urinary symptoms such as increased fre-
quency, urgency, dysuria, incontinence, and recur-
rent infections in addition to pelvic laxity and stress
incontinence. In addition, changes in vaginal pH and
vaginal flora may predispose postmenopausal women
to urinary tract infection and Candida outbreaks 96.
6.1 Evaluation for Infection in Vaginal Atrophy
Vulvar itching, dyspareunia, vulvar and cervical
erythema, vaginal inflammation (with or without cer-
vical inflammation), and often a thick (curdled), white,
non-malodorous vaginal secretion are typical of can-
didiasis. Bacterial vaginosis is characterized by a
creamy or yellow secretion and a fishy odour, espe-
cially when KOH is added to a hanging drop speci-
men. Trichomonas vaginalis is associated with cervi-
cal lesions, friability, microhemorrhagic zones, and
frothy, greenish, foul-smelling vaginal secretions 97.
A definitive diagnosis of vaginal infection (most
commonly Candida albicans, bacterial vaginosis, or
T. vaginalis) is made in only about one third of post-
menopausal women who present with symptoms of
vaginitis. In most of these patients, the symptoms are
the result of estrogen deficiency or nonaerobic bac-
terial infections, local irritants, allergens, or derma-
tologic conditions 98.
To increase the likelihood of diagnosing vaginal
or urogenital atrophy, physicians should routinely
inquire about symptoms such as vaginal irritation or
dryness, decreased lubrication with coitus, or recur-
rent bladder infections. In addition, postmenopausal
women should be encouraged to report these symp-
toms if they do occur, because all are readily correct-
able, but in the absence of treatment they have the
potential to adversely affect quality of life.
In postmenopausal women, the underlying risk
factors for chronic or recurrent vulvovaginal candidi-
asis include immunosuppression caused by medica-
tion or disease, HRT, and uncontrolled diabetes
mellitus 99. The physiologic effects of chronic stress
(such as diagnosis and treatment of breast cancer)
inhibit cellular immune responses that are relevant
to cancer prognosis 100. In fact, physical wellbeing,
mood, and coping effort may affect, and in turn be
affected by, markers of activation of the cellular im-
mune system, as observed at 3 and 6 months of adju-
vant therapy in the International Breast Cancer Study
Group adjuvant clinical trials 101.
Postmenopausal patients at risk for recurrent can-
didiasis should be evaluated and treated the same way
as younger women are 99. In addition to being estro-
gen-deprived, postmenopausal women with recurrent
vulvovaginal candidiasis harbour more aggressive
and resistant fungi 102.
In the diagnosis of vaginal candidiasis, the fol-
lowing symptoms are clinically helpful:
• Vaginal discharge (quantity, color, consistency)—
A “cheesy” discharge is quite symptomatic of
candidiasis, and a thick, curdy, or flocculent white
discharge is strongly predictive of candidiasis; a
watery discharge makes candidiasis less probable.
• Itching—Between 70% and 90% of patients com-
plain of itching.
• Inflammation (redness, pain or burning, swell-
ing)—Vulvar or vaginal edema, erythema, fis-
sures, or excoriations are associated with
candidiasis, although they can also occur in
trichomoniasis.
• Absence of odour (fishy or foul)—A lack of
odour indicates an increased likelihood of can-
didiasis; the presence of an odour perceived by
the patient reduces the likelihood of candidiasis.
• Patient’s self-diagnosis—“Another yeast infec-
TABLE IV Factors that elevate the risk of developing atrophic
vaginitis 95
1. Hormonal:
Estrogen deficiency (menopausal or premenopausal);
decreased ovarian functioning; postpartum loss of
placental estrogen; increased prolactin level during
lactation
2. Illness:
Immunologic abnormalities
3. Therapies:
Radiation, chemotherapy, oophorectomy
Anti-estrogen medications:
Tamoxifen, danazol, oxyprogesterone, leuprolide, nafarelin
4. Lifestyle:
Smoking; stopping sexual activity altogetherDERZKO et al.
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tion” is most probably candidiasis. However, if
the condition fails to resolve with over-the-
counter treatment, or if it recurs, the patient needs
to be examined, and cultures taken.
• Urinary tract symptoms—Women with candidi-
asis may suffer from “external” dysuria 103.
In brief, candidiasis is associated with vulvar pru-
ritus, a cheesy discharge, and redness, and it is often
identified through self-diagnosis. Bacterial vaginosis
is associated with increased discharge and a complaint
of odour. However, microscopic findings are not en-
tirely diagnostic, and primary care clinicians need to
be skilled at screening for vaginal candidiasis, bacte-
rial vaginosis, and trichomoniasis in postmenopausal
women presenting with vulvovaginal complaints 103.
6.2 Clinical Examination for Vaginal Atrophy and
Vaginitis
Gynecologic examination aided by an appropriately
sized speculum should investigate vulvar skin close
to the vagina for signs of dystrophy or other lesions,
including premalignant and malignant disease 96. The
estrogen-sensitive labia majora and minora should
also be examined. Urethral caruncle, prolapse (cys-
tocele, rectocele, enterocele, and uterine prolapse),
the cervix, and pelvic masses should be noted.
6.3 Diagnosis of Vaginal Atrophy and Vaginitis
To confirm urogenital estratrophy vaginitis, pelvic
examination of the vulva and vagina should show
signs of dryness, pallor, redness (if inflamed), and
thinning of tissue 95,96. Pale, smooth, shiny, and dry
vaginal epithelium suggests atrophy.
Urogenital status can be evaluated using the Vagi-
nal Health Index, which assigns a score to a number
of parameters that are used to assess the vaginal epi-
thelium. These include colour, rugosity, moisture and
secretion, elasticity, friability to touch, and pH (which
ideally should be less than 5). A lower index is in-
dicative of vaginal atrophy of greater severity 96. In-
flammatory signs include patch erythema, petechiae,
increased vascularity, friability, and bleeding and dis-
charge, which indicate vaginitis. Vaginal cytology
(especially samples taken from the upper third of the
vagina) for maturation index that shows increased
parabasal and intermediate cells and decreased su-
perficial cells is indicative of lowered estrogen sta-
tus. The normal acidic vaginal pH of 3.5–4.5 in
healthy mature females becomes alkaline after meno-
pause (assessed with a pH indicator strip inserted into
the vagina) and predisposes women to recurrent
vaginitis and urinary tract infections. However, can-
didiasis can occur even at normal vaginal pH (£4.5
or £4.9) 103.
When post-coital bleeding occurs in menopausal
women, an endometrial biopsy becomes necessary
to rule out endometrial pathology, including cancer.
A Pap smear can confirm cervical health. Cervical
bleeding may be the result of estratrophy. The find-
ing of a friable cervix mandates exclusion of cervici-
tis, particularly Chlamydia, because cervicitis is a
more likely cause of post-coital bleeding than is en-
dometrial carcinoma. Furthermore, bleeding from
coital “trauma” in an atrophic, stenotic introitus or
vagina suggests that endometrial carcinoma is un-
likely. Transvaginal ultrasound assessment of the
uterus and particularly of the endometrium is very
helpful, both in atrophic and in well estrogenized tis-
sues. If endometrial ultrasound shows a thickened
endometrium, biopsy is essential to rule out endome-
trial pathology, be it hyperplasia, carcinoma, or an
endometrial polyp. A thin endometrium (usually de-
fined as an endometrial stripe of 4 mm or less) mea-
sured on transvaginal ultrasonography suggests an
atrophic or non-stimulated endometrium. Infection
with Trichomonas, Candida, or bacterial vaginitis
may be a cause of post-coital bleeding. Table V pro-
vides a differential diagnosis of atrophic vaginitis 95.
6.4 Management Options
The guidelines approved by the SOGC recommend ini-
tiation of safe and proven therapies for clinical man-
agement as indicated by basic pelvic examination,
examination of the vulva, and laboratory tests
(Table VI) 60.
6.4.1 Vaginal Atrophy
Options for the management of vaginal atrophy de-
pend on the specific clinical symptoms. Treatment
options range from lifestyle modifications to non-
hormonal and hormonal interventions.
Lifestyle: The SOGC guidelines 60 encourage regular
vaginal coital activity to increase blood circulation
to the pelvic organs and avoidance of products that
pose a risk of contact dermatitis of the vulva. Con-
tact dermatitis of the vulva may be caused by irri-
tants such as perfumed or dyed toilet tissue;
tight-fitting garments, underwear, or bathing suits;
soaps, detergents, or fabric softeners; talcum powder;
TABLE V Differential diagnosis of atrophic vaginitis 95
Infection
Bacterial vaginosis
Trichomoniasis
Contact dermatitis or skin reaction to
Perfumes and deodorants
Powders
Panty liners
Perineal pads
Soaps
Spermicides
Lubricants
Tight-fitting or synthetic fabricMANAGEMENT OF SEXUAL DYSFUNCTION
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hygiene sprays; deodorant pads; spermicidal foams,
creams, or jellies; rubber products, including dia-
phragms or condoms; poison ivy or similar plants;
and talcs 104. The SOGC has emphasized the lack of
evidence to support any beneficial effects of dietary
estrogens or supplements such as dong quai. How-
ever, the SOGC does encourage consumption of pure
cranberry and lingonberry juice concentrates to avoid
urinary tract infections 60,105. Smoking is associated
with decreased estrogen levels and consequent vagi-
nal estratrophy—yet another reason to encourage
smoking cessation 60.
Vaginal Moisturizer: A non-hormonal moisturizing
gel containing purified water, glycerine, mineral oil,
polycarbophil, carbopol 974P, hydrogenated palm oil
glyceride, and sorbic acid (Replens: Wellspring Phar-
maceutical Corporation, Bradenton, FL, U.S.A.)—the
only vaginal moisturizer available in Canada— used
three times weekly has proven efficacy in increasing
vaginal moisture and vaginal fluid and in decreasing
vaginal itching, irritation, and dyspareunia 60,106.
Lubricants for Coital Comfort: Several lubricants
that can be used to reduce immediate irritation dur-
ing coital activity are available to women in Canada,
but no evidence currently exists that these products
have any long-term therapeutic effect 60. Water-
soluble vaginal lubricants that relieve vaginal dry-
ness and moisten tissue can substitute for estrogen 96,
but most water-based lubricants contain glycerine,
and patients prone to yeast infection should avoid
them.
Lubricants for Vaginal Dryness: Orally adminis-
tered or locally applied vitamin E in daily doses of
100–600 IU has been found to increase vaginal lu-
brication and to relieve the dryness and irritation that
accompany atrophic and other forms of vaginitis.
KY Jelly (KY) with vitamin E is another possibility.
Vitamin D and analogs used in postmenopausal os-
teoporosis are also involved in growth and differen-
tiation of stratified squamous epithelium of the
vagina. Homeopathic and natural health supplements
of bryonia, belladonna, lycopodium have been used,
although these remedies have failed in randomized
trials of safety and efficacy.
Hormonal Therapies for Urogenital Atrophy,
Vaginitis, and Dyspareunia: In general, non-hor-
monal treatments are the first-line recommendation
in breast cancer patients 107,108. However, expert rec-
ommendations reviewed and revised by the Breast
Disease Committee of SOGC concluded that HRT after
treatment for breast cancer has no adverse impact on
recurrence and mortality, and therefore HRT is an op-
tion in postmenopausal women with previously
treated breast cancer. Careful evaluation of the indi-
cation for HRT and limiting the duration of postmeno-
pausal  HRT to the shortest duration possible were
recommended 37. However, the findings from the
HABITS and Stockholm trials raise additional questions
and emphasize the need for careful consideration,
review, and collaborative discussion of all the risks
and benefits in each individual case. Some evidence
also suggests that the small risk of ovarian cancer
and endometrial cancer observed with HRT is evident
only with therapies that use estrogen alone 109.
Because minimal systemic absorption occurs with
use of the recommended doses, the opinion of the
SOGC is that women with a history of breast cancer
may still use local intravaginal estrogen preparations
in the recommended doses for the treatment of symp-
toms of urogenital atrophy 110. Tested topical estro-
gen replacement therapies available in Canada include
a conjugated equine estrogen (CEE) cream, vaginal
estradiol tablets, and an estradiol-containing Silastic
vaginal ring.
Available systemic estrogen therapies (oral and
transdermal patches, and gels) reduce vasomotor
symptoms (hot flashes) and sleep disturbance. They
also estrogenize urogenital tissues, although, not un-
commonly, additional local treatment (vaginal tab-
lets, creams, rings) is needed. The Canadian
Consensus Conference on Menopause and 2006 Up-
dated SOGC guidelines and recommendations 43 indi-
cate that local estrogen can ameliorate dyspareunia
TABLE VI Society of Obstetricians and Gynaecologists of Canada clinical practice guidelines for the detection and management of vaginal
atrophy 60
Guideline Level of evidence
1. Routine clinical assessment of postmenopausal women for symptoms and signs of vaginal atrophy. (III-C)
2. Regular sexual activity to maintain vaginal health. (II-2B)
3. Consumption of pure cranberry or lingonberry juice (rather than cranberry drink) to reduce the risk of recurrent
urinary tract infections. (I-A)
4. For the treatment of local urogenital symptoms such as vaginal itching, irritation, and dyspareunia, regular
application of vaginal moisturizers is an alternative to hormone replacement therapy. (I-A)
5. Vaginal estrogen replacement therapies for vaginal atrophy:
Conjugated equine estrogen cream (I-A)
Sustained-release intravaginal estradiol ring (I-A)
Low-dose estradiol tablet (I-A)
6. Vaginal estrogen therapy for menopausal women experiencing recurrent urinary tract infections. (I-A)DERZKO et al.
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associated with vulvovaginal atrophy. Low doses may
suffice. For example, half an applicator of CEE cream
(Premarin) intravaginally once or twice weekly, or
one intravaginal estradiol tablet (Vagifem) twice
weekly is usually adequate. On occasion, a small
amount of CEE cream (less than dime size) applied to
the peri-introital and peri-urethral area once weekly,
or even less frequently, may provide symptomatic
relief with minimal dosing.
An alternative treatment proposed in the SOGC
guidelines is use of a sustained-release intravaginal
ring that slowly and constantly releases 5–10 mg of
estradiol daily from its estradiol-loaded core over a
3-month period. Use of the Estring (Pfizer Canada)
effectively relieves symptoms of atrophic vaginitis
and restores normal vaginal pH and cytology, main-
tains serum estradiol levels in the menopausal range,
and does not induce endometrial proliferation 111.
Despite the efficacy of vaginal estrogen prepara-
tions in treating vaginal atrophy, a small study of
7 postmenopausal women on AIs who were using
Vagifem vaginal estradiol tablets noted an increase
in serum estradiol levels (>19 pmol/L over low base-
line postmenopausal estradiol levels) that it was feared
might reverse the activity of the AIs being used
(Table VII) 112. Despite the very small size of this study,
physicians are cautioned, in the absence of other re-
assuring data, to avoid this treatment combination and
to recommend non-hormonal preparations instead.
Although good data from Sarrel 68 and others
suggest that estrogen therapy (possibly including
vaginal estrogen treatment) improves local genital
sensitivity and sexual response, thereby potentially
improving sexual interest and motivation 44, others
disagree. Safety is the overriding consideration. In
the opinion of the SOGC, as reported in their clinical
practice guidelines 107, the presence of estrogens at
concentrations considerably higher than those at-
tained with current HRT preparations does not nega-
tively influence the efficacy of breast cancer
management, as has already been demonstrated by
other studies 113–115. Data from ongoing prospective
randomized clinical trials should offer definitive
conclusions.
In brief, if appropriate, replacement of missing
hormones or enhancement of depleted levels in breast
cancer patients can add to quality of life and should
be considered in particular for the treatment of vagi-
nal dryness.
7. CONCLUSIONS
The gynecologic signs and symptoms associated with
diminished estrogen levels can affect, to varying de-
grees, the quality of life for postmenopausal women
receiving adjuvant AI therapy. In addition to the di-
rect sexual side effects related to diminished estro-
gen, initiation of treatment for breast cancer often
results not only in early and more severe menopausal
symptoms, but also in fear and anxiety, body image
concerns, and sexual dysfunctions related to altered
pelvic health. Because of the complexity of FSD, a
biopsychosocial approach to assessment and man-
agement is necessary. A detailed sexual history ad-
dressing specific sexual concerns is a therapeutic
intervention in itself. Besides genital functioning, is-
sues affecting sexual health may encompass bladder
and bowel difficulties, mobility limitations, pain, fa-
tigue, and issues with self-image and self-esteem.
The AIs offer numerous advantages over tamoxi-
fen for the treatment of early breast cancer in post-
menopausal women: fewer gynecologic adverse
events, fewer hot flashes, fewer endometrial abnor-
malities (including fewer polyps, less hyperplasia, and
a lower incidence of endometrial cancer), and over-
all, fewer diagnoses requiring a hysterectomy. For
the woman with breast cancer, avoiding the invasive
and uncomfortable diagnostic and therapeutic inter-
ventions associated with uterine abnormalities can
have a tremendous impact on quality of life. Clinical
evaluation of AI therapy–associated signs and symp-
toms of urogenital atrophy, vaginitis, dyspareunia,
and loss of sexual interest demonstrates several simi-
larities with natural age- and menopause-related gy-
necologic events associated with diminished estrogen
levels. Management of these events through a com-
bination of lifestyle modification, counselling, and
hormonal and non-hormonal interventions can there-
fore improve quality of life significantly for patients.
Despite the lack of a pharmacologic “gold stan-
dard” for the treatment of female sexual concerns,
therapeutic regimens can be tailored to effectively
address each area of distress—psychologic, interper-
sonal, sociocultural, and physiologic—in the affected
functional domains of desire, arousal, and orgasm.
Hormone replacement therapies such as the intra-
vaginal ring with a sustained-release estradiol-loaded
core (Estring) recommended by SOGC have proven ef-
fective in improving patient compliance for symptom-
atic relief of atrophic vaginitis and in restoring normal
vaginal pH and cytology without side effects of en-
dometrial proliferation or a significant rise in systemic
estradiol levels. Recommended alternatives are estra-
diol tablets (Vagifem) and low doses of CEE cream
(Premarin). Preliminary data suggest that androgens
TABLE VII Estradiol levels in women on Vagifem (Novo Nordisk,
Princeton, NJ, U.S.A.) and aromatase inhibitor therapy 112
Patient Concurrent AI Estradiol level on Vagifem (pmol/L)
Baseline 2 Weeks 4 Weeks
1 Letrozole <3.0 220 40
2 Letrozole <3.0 232 31
3 Letrozole =3.5 77 16
4 Anastrozole <3.0 46 2.4 a
a Experienced a 10-day break from Vagifem before this
measurement.MANAGEMENT OF SEXUAL DYSFUNCTION
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alone or the addition of testosterone to a common es-
trogen–progestogen regimen may inhibit the stimula-
tory effects of estrogens and progestins on breast cell
proliferation and may, in fact, lead to apoptosis of
cancer cells. However, these results are preliminary;
long-term safety data are lacking. Furthermore, few
studies have looked at the relationship between test-
osterone therapy and breast cancer risk in postmeno-
pausal women, and thus no definitive answers are
available to guide patient management 76.
In view of recent findings raising concerns over
elevated circulating estradiol levels in breast cancer
patients on AI therapy who are using transvaginal es-
trogenic preparations, non-hormonal therapies includ-
ing regular application of vaginal moisturizers and
lubricants are recommended and certainly should be
first-line therapy. In addition, pelvic therapy for pel-
vic tone awareness and pelvic floor exercises (for
example, Kegel exercises) and lifestyle modification
are preferred and should be considered early.
The sexual context within which the patient ex-
ists is the key factor that needs to be assessed before
any medical intervention is added. Concerns that in-
terfere with sexuality (including bladder and bowel
issues, motor and sensory changes, and management
of menopausal symptoms in general), other chronic
medical conditions, and sexual self-esteem and part-
ner relationships are all importance parts of the
patient’s sexual context, and any effective interven-
tion must account for all of them. Psychological in-
tervention and sex counselling are important adjuncts
in the comprehensive management of these patients,
and interventions should be considered and provided
as needed.
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APPENDIX A: SEXUAL HISTORY QUESTIONNAIRE 41,42,43
of desire? Anything you think was responsible?
3. Do you have any inhibitions or thoughts that interfere
with your level of desire?
4. Do you currently participate in sexual activities despite
your altered level of desire? If so, what motivates
you?
5. Any spontaneous sexual thoughts or fantasies?
6. Are you aroused by erotic descriptions in books or sex
scenes in movies?
7. How often do you masturbate?
8. Do you find your partner attractive? Do you find other
men or women attractive?
F. Sample questions for women with decreased arousal:
When did you notice a change in your level of arousal? What
do you think is responsible for the change?
Do sexual thoughts, fantasies, reading a sexy passage in a
book, or seeing a sexy scene in a movie “turn you on”?
Does touching your different body parts (by yourself or your
partner) arouse you? If so, do you feel stimulated or
titillated? Does the sensation last long enough or quickly
plateau?
Are there any distracting feelings or thoughts that seem to
inhibit these sensations? Have you ever been abused
sexually, and do still suffer from negative memories that
affect your enjoyment now?
Does masturbation offer you real pleasure or just momentary
thrill?
Are there any sexual activities that you and your partner(s)
engage in for pleasure?
Did you try using a vibrator or other sex toys? If so, do you
find them indispensable?
Are you comfortable talking with your partner(s) about the
kinds of stimulation you enjoy?
Do you find your partner(s) responsive when you talk about
sex?
Have you tried using lubricants for vaginal dryness? Which
ones? Do you find them helpful?
G. Sample questions for women with difficulty achieving
orgasm
Have you ever had an orgasm or heard of female genital
structures, such as the clitoris?
Did you know that most women require stimulation of the
clitoris to become fully aroused?
Do you participate in sexual activities that involve stimula-
tion of the clitoris?
Does sexual stimulation give you pleasure? If yes, can you
identify inhibiting feelings or thoughts that interfere with
arousal and prevent orgasm?
When was the last time you noticed a change in your ability
to achieve orgasm? Can you identify anyone or anything
that you feel might have been responsible for the change?
Can you describe exactly what you feel? But are you able to
achieve orgasm at all? Or does it take longer? Did you
find certain type of stimulation working better than
others?
Do you really get distracted during an orgasm?
Do you always expect to have an orgasm when you have
sex? Or are you satisfied even without achieving orgasm?
A. Functional history
1. What functions are affected currently?
2. When did you start noticing a change in your interest in
sex?
3. Do you have problems with arousal or getting sufficiently
lubricated?
4. Are you able to reach orgasm?
5. How often do you experience discomfort or pain during
sex?
B. Assessment of chronic dyspareunia (SOGC guidelines)
1. Is vaginal entry possible at all (that is, with finger, penis,
speculum, tampon)?
2. Do you get sexually aroused at the beginning of and
during intercourse?
3. Exactly when does the pain arise?
During entry of penile head?
With partial penile entry?
With deep penetration?
With movement of the penis?
During or following ejaculation?
Following subsequent urination?
Several minutes after attempted or successful intercourse
or other vaginal stimulation attempts?
4. Is there less or greater degree of pain at times, and any
idea why?
C. Comprehensive questions related to:
1. Acuteness or severity of the problem (global vs local)
2. Chronicity of the problem (primary vs secondary)
3. Circumstances underlying the problem
4. Medical conditions and current medications
5. Low desire:
Serious illness, depression, hypothyroidism, hyperprolac-
tinemia, central nervous system depressants, dopamine
receptor blockers, selective serotonin reuptake
inhibitors (SSRIs), anti-androgens
6. Decreased arousal:
Atherosclerosis, diabetes, pelvic trauma, pelvic surgery,
pelvic irradiation, multiple sclerosis and other illness
associated with neurogenic impairment, SSRIs, anti-
estrogens, anticholinergic medications
7. Difficulty attaining orgasm:
Same as for decreased arousal
8. Medical conditions that might contraindicate potential
therapeutic options:
Thromboembolism, active liver disease, hormone-respon-
sive cancers, severe acne (estrogen, testosterone)
9. Eating disorders, seizures (bupropion)
10. Patient’s level of distress, reasons for seeking help, and
response to previous interventions
D. Evaluation of couple individually and together for:
1. Sexual communication
2. Technical skill
3. Sexual repertoire
E. Sample questions for women with hypoactive sexual desire
disorder (HSDD)
1. On a scale of 0–10, how would you rate your level of
desire currently and when it was the highest?
2. When was the last time you found a change in your level